| Literature DB >> 27240459 |
Fan Yang1,2,3,4, Hao Jin1,2,3, Jian Wang1,2,3, Qian Sun1,2,3, Cihui Yan1,2,3, Feng Wei1,2,3, Xiubao Ren5,6,7,8.
Abstract
Adoptive cellular therapy (ACT) with various lymphocytes or antigen-presenting cells is one stone in the pillar of cancer immunotherapy, which relies on the tumor-specific T cell. The transfusion of bulk T-cell population into patients is an effective treatment for regression of cancer. In this chapter, we summarize the development of various strategies in ACT for cancer immunotherapy and discuss some of the latest progress and obstacles in technical, safety, and even regulatory aspects to translate these technologies to the clinic. ACT is becoming a potentially powerful approach to cancer treatment. Further experiments and clinical trials are needed to optimize this strategy.Entities:
Keywords: Adoptive cellular therapy; Cancer treatment; Combination therapy
Mesh：
Substances：
Year: 2016 PMID： 27240459 DOI： 10.1007/978-94-017-7555-7_4
Source DB: PubMed Journal: Adv Exp Med Biol ISSN： 0065-2598 Impact factor: 2.622